<DOC>
	<DOCNO>NCT00070837</DOCNO>
	<brief_summary>The purpose study determine high dose MLN2704 give multiple time safely patient prostate cancer , identify side effect associate take drug . This study also evaluate MLN2704 take , broken eliminate body .</brief_summary>
	<brief_title>MLN2704 Subjects With Metastatic Androgen-Independent Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Histologic cytologic diagnosis ( recent remote ) prostate adenocarcinoma Radiographic evidence ( recent remote ) metastatic prostate adenocarcinoma 18 year age older Progressive prostate cancer define presence one follow despite castrate level testosterone ( testosterone &lt; 50 ng/dL ) : 1 . Progressive tumor lesion ( change size lymph node parenchymal mass physical examination Xray CT scan MRI ) 2 . Progressive bone metastasis ( presence new lesion ( ) bone scan ) 3 . Progressive PSA level ( define Section 3.6.1 ) Subjects receive antiandrogen must show progression disease follow discontinuation antiandrogen Subjects must remain luteinizing hormonereleasing hormone ( LHRH ) analog therapy duration trial unless surgically castrate Agree use effective barrier method contraception . Exclusion criterion : Testosterone &gt; 50 ng/dL Use corticosteroid and/or adrenal hormone inhibitor within 4 week dose Use PCSPES within 4 week dose Prior cytotoxic chemotherapy and/or radiation therapy within 6 week dose Use antiandrogen therapy ( eg , flutamide , bicalutamide , nilutamide ) within 6 week dose Prior monoclonal antibody administration , include ProstascintÂ® Peripheral neuropathy &gt; Grade 2 , define NCI Common Toxicity Criteria Adverse Events ( NCI CTCAE ) History CNS metastasis , include incompletely treat epidural disease History Hepatitis B C History seizure disorder require active treatment and/or stroke History HIV infection Platelet count &lt; 100,000/mm3 Absolute neutrophil count ( ANC ) &lt; 1,500/mm3 Hematocrit &lt; 27 percent Abnormal coagulation profile ( elevated PT , and/or INR , PTT ) Serum creatinine &gt; 2.0 mg/dL , creatinine clearance &lt; 60 mL/min serum creatinine &gt; 2.0 mg/dL AST ALT &gt; 1.5 x ULN Bilirubin ( total ) &gt; 1.25 x ULN Serum calcium &gt; 12.5 mg/dL Active serious infection control antibiotic Active angina pectoris NY Heart Association Class IIIIV heart disease Karnofsky Performance Status &lt; 60 % Life expectancy &lt; 6 month Other serious illness ( e ) involve cardiac , respiratory , CNS , renal , hepatic hematological organ system might preclude completion study interfere determination causality adverse effect experience study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
</DOC>